At an American Diabetes Association annual meeting, Merck released data showing its Januvia lowered blood glucose levels in Type 2 diabetics while Pfizer showed its inhaled insulin treatment Exubera was effective at lowering or maintaining blood sugar levels in Type 1 and some Type 2 diabetics, both without serious side effects. Merck hopes to receive FDA approval for Januvia in October, while a similar drug, Novartis' Galvus, is expected to be approved by early 2007.

Related Summaries